Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larynx-IO 2.0: Neoadjuvant Toripalimab and Chemotherapy in Laryngeal/Hypopharyngeal Cancer
NCT06039631Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2023
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in laryngeal squamous cell carcinoma (LSCC), hypopharyngeal squamous cell carcinoma (HSCC), sponsored by Fudan University. Started Aug 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
laryngeal squamous cell carcinoma (LSCC)hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT06039631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039631.